Get started
GSK plcGSK plcGSK plc

GSK plc

No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonalsOptionsBondsETFs

Chart


Full chart

Key facts today


GSK’s RSV vaccine Arexvy is under ACIP review for possible expanded adult use (18–49 at increased risk). ACIP guidance is paused, potentially delaying wider coverage decisions.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪115.87 B‬ USD
Dividend yield (indicated)
3.04%
Price to earnings Ratio (TTM)
15.93
Basic EPS (TTM)
3.72 USD
Net income (FY)
‪7.53 B‬ USD
Revenue (FY)
‪43.05 B‬ USD
Shares float
‪2.00 B‬
Beta (1Y)
0.56

About GSK plc


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Luke Miels
Website
gsk.com
Headquarters
London
IPO date
May 22, 1972
Identifiers
3
ISIN US37733W2044
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Check out other big names from the same industry as GSK.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


5.858% YTM
Maturity date Apr 10, 2042
Coupon 5.25% (Fixed)
5.685% YTM
Maturity date Mar 9, 2039
Coupon 6.38% (Fixed)
5.612% YTM
Maturity date Dec 18, 2045
Coupon 4.25% (Fixed)
5.345% YTM
Maturity date May 12, 2035
Coupon 1.63% (Fixed)
5.300% YTM
Maturity date Mar 18, 2043
Coupon 4.20% (Fixed)
4.999% YTM
Maturity date May 15, 2038
Coupon 6.38% (Fixed)
4.854% YTM
Maturity date Dec 19, 2033
Coupon 5.25% (Fixed)
4.728% YTM
Maturity date Apr 15, 2035
Coupon 4.88% (Fixed)
4.667% YTM
Maturity date Apr 15, 2034
Coupon 5.38% (Fixed)
4.593% YTM
Maturity date Oct 12, 2028
Coupon 1.25% (Fixed)
4.152% YTM
Maturity date Apr 15, 2030
Coupon 4.50% (Fixed)

See all GSK bonds 

ETFs holding the stock


AVDE
Avantis International Equity ETF
Weight 0.45%
Market value ‪69.84 M‬
FENI
Fidelity Enhanced International ETF
Weight 0.61%
Market value ‪55.76 M‬
PPH
VanEck Pharmaceutical ETF
Weight 4.78%
Market value ‪48.74 M‬
FVD
First Trust VL Dividend
Weight 0.45%
Market value ‪37.24 M‬
FTHI
Fidelity Tactical High Income Fund Trust Units
Weight 0.52%
Market value ‪35.08 M‬
AVIV
Avantis International Large Cap Value ETF
Weight 1.21%
Market value ‪15.20 M‬
GMOI
GMO International Value ETF
Weight 3.36%
Market value ‪14.88 M‬
RODM
Hartford Multifactor Developed Markets (ex-US) ETF
Weight 0.95%
Market value ‪14.08 M‬
DFAX
Dimensional World ex U.S. Core Equity 2 ETF
Weight 0.11%
Market value ‪13.04 M‬
AQEC
AQE Core ETF
Weight 2.12%
Market value ‪12.44 M‬
TOUS
T. Rowe Price International Equity ETF
Weight 0.66%
Market value ‪9.34 M‬

Explore more ETFs